Testing a new drug combined with immunotherapy for advanced cancers

Plain-English translation of NCT06270706 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated October 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage trial testing a new medication called , often given together with (a type of immunotherapy), in people with advanced or metastatic solid tumors that have stopped responding to immunotherapy. The trial aims to find the right dose of this medication and see whether it can help people whose cancers have become resistant to standard immunotherapy treatment.

Some people with advanced cancers initially respond well to immunotherapy like , but their cancer eventually starts growing again. This trial exists to see if adding this new treatment might help patients whose cancers have become resistant to immunotherapy alone.

Do you qualify?

You likely qualify if…

you have been diagnosed with an advanced or metastatic solid tumor confirmed by a biopsy or imaging
you have received at least 12 weeks of continuous immunotherapy (anti-PD-1 or anti-PD-L1 treatment) as a single drug or combined with other cancer treatments
your cancer initially responded to immunotherapy (either shrank significantly or stayed stable for at least 6 months) but has since started growing again
you have measurable tumors that can be tracked on scans or imaging tests
you are expected to live at least 3 months, and you have adequate bone marrow and organ function

You likely don't qualify if…

you have an autoimmune disease that has required treatment in the past 2 years, as the medication may worsen this condition
you have cancer that has spread to your brain and is causing symptoms or requiring active treatment
you have significant heart disease or are currently taking high doses of steroids (more than 10 mg daily)
you have an active infection like uncontrolled HIV, hepatitis B, or hepatitis C
you have had major surgery within the past 4 weeks or have not recovered from recent surgery

What participation looks like

In the first part of the trial, you would receive the medication by mouth twice or three times daily (or in some cases twice daily at higher doses) combined with infusions, while researchers carefully monitor your safety and how your body responds. In the second part, you might receive the medication alone or combined with , depending on which group you're assigned to. You would have regular clinic visits for blood tests, imaging scans, and physical exams to check how well the treatment is working and to watch for any side effects.

AI-generated summary from trial data · Oct 2, 2026 · Not medical advice

Testing a new drug combined with immunotherapy for advanced cancers

What is this trial?

Do you qualify?

What participation looks like

Trial locations